Surgalign Holdings (Nasdaq: SRGA) recently announced the 100th case completed with its recently launched Cortera spinal fixation system,
Deerfield, Illinois–based Surgalign engaged in a limited market release of Cotera shortly after FDA 510(k) clearance in August.
Surgalign has used the initial market release to collect clinical and design feedback on the system from a wide range of spine surgeons. The company is now seeking to secure additional products. It plans to develop additional implants and instruments to add to the Cortera system over the next three to four years. In addition, it is working to integrate Cortera with its Holo Portal surgical guidance system.
Surgalign’s plan is to ramp up commercialization in the first half of 2023. It looks to grow its market share in what it says is an estimated $2.2 billion U.S. posterior fixation market.
“Cortera represents the first organically developed product at Surgalign, and we believe holds great promise for our company and our customers. Market reception has been very strong to date, and we look forward to moving into the next phase of our commercial launch in 2023, while continuing to drive innovation in the system,” Surgalign CEO Terry Rich said in a Dec. 15 news release.
Cortera is a 5.5/6mm rod pedicle screw system. It offers both open and minimally invasive surgery (MIS) modules. Plus, there’s a feature-rich screw design with a comparatively low profile and a newly designed locking mechanism.
